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Abstract
AIM: To compare histological endpoint assessment us-
ing noninvasive alternatives to biopsy during treatment 
in a chronic hepatitis C virus (HCV) cohort.
METHODS: Patients with chronic HCV were randomized 
to receive interferon-based therapy for 24 (genotypes 
2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was 
assessed at baseline and at week-12 post-treatment 
follow-up. Baseline biopsy for METAVIR was assessed 
by a single pathologist. FibroScan® transient elastogra-
phy (TE) was performed during treatment in a patient 
subset.
RESULTS: Two thousand and sixty patients (n  = 253 
in Asia) were classified as METAVIR F0-1 (n = 1682) or 
F2-4 (n  = 378). For F2-4, FS (n  = 2055) had sensitiv-
ity and specificity of 0.87 and 0.61, respectively, with 
area under the receiver-operating curve of 0.82; corre-
sponding values for TE (n  = 214) and combined FS/TE 
(n  = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 
0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 
0.41) and higher in Asians vs  non-Asians (κ = 0.86 vs  
0.35; P  < 0.001). Combined FS/TE had 97% accuracy 
in Asians (n  = 33). Baseline FS (0.38 vs 0.51, P  < 0.001) 
and TE (8.0 kPa vs 11.9 kPa, P  = 0.006) scores were 
lower in patients with sustained virological response 
than in nonresponders, and were maintained through 
follow-up.
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CONCLUSION: FS and TE may reliably differentiate mild 
from moderate-advanced disease, with a potential for 
high diagnostic accuracy in Asians with chronic HCV.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Complications of  chronic hepatitis C virus (HCV) infec-
tion occur as a consequence of  progressive liver fibro-
sis, leading to cirrhosis, liver failure, and hepatocellular 
carcinoma. Histological assessment of  liver injury and 
fibrosis is important for making treatment decisions, as 
well as for predicting prognosis and therapeutic outcome, 
in chronic liver disease[1]. Liver biopsy is, however, an 
invasive procedure, limited by issues relating to sampling, 
cost and morbidity, and only provides a static measure 
of  fibrosis[2]. Accurate noninvasive methods of  monitor-
ing changes in fibrosis would be helpful in following the 
natural history of  the disease and monitoring potential 
antifibrotic responses to antiviral or other treatment mo-
dalities. The past decade has seen the development of  
several noninvasive predictive indices for hepatic fibrosis 
based on direct and indirect serum markers, as well as 
imaging modalities to measure liver stiffness, such as 
transient elastography (TE) (FibroScan®, Echosens, Paris, 
France)[3]. Serum HCV FibroSURE™ (FS) (Laboratory 
Corporation of  America, Raritan, NJ, United States) 
combines α2-macroglobulin, haptoglobin, γ-glutamyl 
transpeptidase, apolipoprotein A1, alanine transaminase, 
and total bilirubin into a proprietary algorithm for fibro-
sis and inflammatory activity[4]. Both noninvasive mo-
dalities have been extensively evaluated in viral hepatitis 
and other chronic liver diseases[5]. The combination of  
serum tests, such as FS or FibroMeters, and TE appears 
to improve the cross-sectional diagnostic accuracy for 
advanced-stage disease in chronic HCV[6,7]. The French 
Haute Autorité de Santé has approved FS and TE as first-
line tests to detect cirrhosis in chronic HCV[8]. Few stud-
ies, however, have determined the utility of  either bio-
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markers or TE to accurately follow longitudinal changes 
in fibrosis both during and after antiviral therapy to 
better define long-term histological outcomes in chronic 
HCV[9-12]. Although there are emerging studies of  TE in 
Asian patients with chronic liver disease (mostly due to 
chronic hepatitis B virus), no studies have evaluated the 
utility of  both FS and TE in Asian patients with chronic 
HCV[13,14]. 
The aims of  the present study were to: (1) compare 
the diagnostic utility of  FS and TE for fibrosis at base-
line in treatment-naïve patients with chronic HCV; (2) 
determine concurrent changes in both FS and TE with 
virological responses during and after albinterferon alfa-
2b (albIFN) combination therapy; and (3) evaluate the 
performance of  these noninvasive tests for the detection 
of  significant fibrosis in an Asian cohort.
MATERIALS AND METHODS
Study population
Adult patients with chronic HCV genotype (Gt) 1 or 2/3 
(n = 2225) who had not previously received interferon 
(IFN)-α therapy were enrolled in two global phase Ⅲ 
studies of  albIFN conducted at 136 centers worldwide 
between December 2006 and October 2008 (ClinicalTri-
als. gov nos. NCT00402428 and NCT00411385)[15,16]. 
Patients were excluded if  they had decompensated liver 
disease or other causes of  chronic liver disease, includ-
ing co-infection with hepatitis B virus or human im-
munodeficiency virus; a significant co-existing medical 
condition; Gilbert’s disease; or alcohol or drug depen-
dence. Patients were randomized in a 1:1:1 ratio to one 
of  three open-label treatment groups: albIFN 900 or 
1200 µg every 2 wk, or PEGinterferon alfa-2a (PEGA-
SYS®, Hoffmann-La Roche Inc., Nutley, NJ) 180 µg 
once weekly. All patients also received oral ribavirin (RI-
BASPHERE®, 3 Rivers Pharmaceuticals®, Warrendale, 
PA, United States) 800 mg/d (Gt 2/3) or 1000-1200 mg/d 
(Gt 1) in two divided doses. Treatment duration was 24 
(Gt 2/3) or 48 (Gt 1) wk, with follow-up at week 48 or 
72, respectively, for sustained virological response (SVR) 
assessment. Patients with detectable HCV RNA at post-
treatment week-12 follow-up were determined to be 
nonresponders (NRs) and were not required to complete 
final follow-up at post-treatment week 24. Serum HCV-
RNA levels were measured by real-time polymerase chain 
reaction assay (COBAS® Ampliprep/COBAS® Taqman® 
HCV Test, Hoffman-La Roche): limit of  detection was 15 
IU/mL and lower limit of  quantitation 43 IU/mL.
All patients provided written informed consent and 
the institutional review boards of  all participating centers 
approved the studies, which were performed in accor-
dance with the Helsinki Declaration of  1975. The authors 
accept full responsibility for the accuracy of  the whole 
content, including findings, citations, and references con-
tained in this manuscript.
Procedures for fibrosis assessment
Pretreatment liver biopsies were available in 2060 pa-
tients, and evaluated for METAVIR fibrosis stage and 
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activity grade by a single pathologist (Torbenson M) who 
was blinded to study assignments or results. Adequate bi-
opsy quality was based on assessment by the pathologist 
of  specimens ≥ 15 mm in length and/or including ≥ 6 
portal tracts. The METAVIR scoring system classifies fi-
brosis on a five-point scale: F0 = no fibrosis; F1 = portal 
fibrosis without septa; F2 = few septa; F3 = numerous 
septa without cirrhosis; and F4 = cirrhosis; necro-inflam-
matory activity is graded on a 4-point scale: A0 = none; 
A1 = mild; A2 = moderate; and A3 = severe[17].
Fasting serum samples were frozen at -70 ℃ within 
2 h of  collection. Assessment with FibroSURE, a com-
mercial serum marker panel assay, was performed in-
dependently, with blinding of  clinical and pathologic 
assessments at a central laboratory (Laboratory Corpora-
tion of  America), at baseline and 12 wk after the end of  
treatment. The TE measurements were obtained using 
FibroScan at baseline, weeks 12, 24 and 48, and 12 wk af-
ter the end of  treatment in patients with HCV Gt 1, and 
weeks 12, 24 and 36 with Gt 2/3, at 40 study sites as part 
of  a protocol-specified substudy. Results of  TE with ≥10 
acquisitions, a success rate ≥ 60%, and an interquartile 
range < 30% of  the median value were considered valid 
measurements, as per manufacturer’s recommendation 
and prior studies[3,18,19].
Statistical analysis
Patient demographic and clinical laboratory characteristics 
were descriptively summarized, and reported as mean 
± SD and range. All tests were two-sided, and statistical 
significance was assessed at the 0.05 level. Performance 
characteristics differentiating mild (F0-1) from moderate-
severe (F2-4) fibrosis at baseline were determined for 
FS. Performance of  this assay for F2-4 was determined 
by area under the receiver-operating characteristic curve 
(AUROC) using the DeLong method[20]. Values for AU-
ROC were standardized relative to a uniform prevalence 
distribution, and an adjusted AUROC was calculated to 
account for spectrum bias, using the difference between 
the mean stage of  advanced fibrosis minus the mean 
stage of  nonadvanced fibrosis[21]. The FS modality pro-
vides a continuous regression index with a correspond-
ing predicted individual fibrosis stage[22]. An FS index < 
0.32 was used for stage F0-1. For two-stage predictive 
indices with FS for F0-1, F1-2, and F3-4, the midpoint 
index value was used as a threshold for assignment of  
stage for analysis. The TE cut-off  values were chosen 
via AUROC analysis as the point at which sensitivity 
and specificity were maximized. Recommended thresh-
olds for TE in chronic HCV of  > 7 kPa and > 12.5 kPa 
for F2 and F4, respectively, were also assessed[6]. For as-
sessing the utility of  combined FS and TE, prediction 
was based on a logistic-regression model containing both 
indices, as well as their pairwise interaction. The measure 
of  agreement chosen was Cohen’s κ. Differences between 
continuous variables were assessed by Student’s t test, as-
suming unequal variance. All statistical analyses were per-
formed using SAS® 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient demographics
Baseline biopsy (mean length 17 mm ± 9 mm) results 
were available from 2060 patients with chronic HCV. Pa-
tients were mostly men (58.1%) and caucasian (77.6%), 
with a mean age of  45.2 ± 11.4 years and a prevalence of  
significant fibrosis of  18.3% (Table 1).
Baseline FibroSURE performance
Results for FS and biopsy were available in 2055 patients. 
For stages F2-4, FS had a sensitivity of  0.87, a specificity 
of  0.61, and an AUROC of  0.82 [95% confidence inter-
val (CI) 0.80-0.84, Figure 1]; the corresponding adjusted 
AUROC relative to a uniform prevalence distribution 
was 0.84. For F4, sensitivity was 0.63, specificity was 0.85, 
and AUROC was 0.83 (95% CI 0.79-0.86). The misclas-
sification rate for FS was 34% (n = 703/2055), and most 
of  these patients (93%; n = 653) were false-positive F2-4 
(Figure 2). For biopsy specimens > 15 mm and F2-4 
(46.0%; n = 948/2055), sensitivity was 0.86, specific-
ity was 0.61, and AUROC was 0.83 (95% CI 0.80-0.86). 
The FS misclassification rate, however, remained 34% in 
these patients with longer biopsy specimens. For biopsies 
> 15 mm and F4, sensitivity was 0.67, specificity was 0.84, 
and AUROC was 0.86 (95% CI 0.81-0.91). For moderate-
severe necro-inflammatory activity of  A2-3, sensitivity 
and specificity were both 0.66, and AUROC was 0.71 (95% 
CI 0.69-0.73).
Baseline TE
Results of  TE and biopsy were available in 214 patients. 
For stage F2, TE > 10.1 kPa had a sensitivity of  0.77, a 
specificity of  0.88, an AUROC of  0.88 (95% CI 0.82-0.93), 
Table 1  Baseline patient demographics  n  (%)
Host characteristics All
(n  = 2060)
Patients with TE 
(n  = 214)
Mean age ± SD (yr)      45.2 ± 11.4         45.7 ± 11.7
Race
   Caucasian        1599 (77.6)       169 (79.0)
   Black 98 (4.8) 5 (2.3)
   Asian 322 (15.6) 39 (18.2)
   Other 41 (2.0) 1 (0.5)
Genotype 
   1        1186 (57.6)       120 (56.1)
   2/3 874 (42.4) 94 (43.9)
Male sex        1196 (58.1)       105 (49.1)
Mean BMI ± SD    26.6 ± 5.1   25.1 ± 4.2
ALT > 1.5 �� �LN 911 (44.2) 98 (45.8)
Mean biopsy length ± SD (mm) 17.0 ± 9.1         15.8 ± 8.2
METAVIR fibrosis stage
   F0 740 (35.9) 80 (37.4)
   F1 942 (45.7) 91 (42.5)
   F2          159 (7.7)         16 (7.5)
   F3          101 (4.9)           9 (4.2)
   F4          118 (5.7)         18 (8.4)
METAVIR activity
   A0-1        1125 (54.6)       126 (58.9)
   A2-3 935 (45.4) 88 (41.1)
ALT: Alanine transaminase; BMI: Body mass index; SD: Standard devia-
tion; TE: Transient elastography; �LN: �pper limit of normal.
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and an adjusted AUROC of  0.88 (Figure 1). For F4, 
TE > 11.7 kPa had a sensitivity of  0.94, a specificity of  
0.88, and an AUROC of  0.93 (95% CI 0.88-0.98). The 
misclassification rate for TE was 14% (n = 31), with ap-
proximately two-thirds of  these patients (68%; n = 21) 
classified as false-positive F2-4. For F2-4 with biopsy 
specimens > 15 mm (39.3%, n = 84; F2-4 prevalence 
22.6%, n = 19), sensitivity was 0.63, specificity was 0.91, 
and AUROC was 0.83 (95% CI 0.72-0.93).
Performance characteristics of  TE, using a previously 
recommended threshold of  > 7 kPa for stages F2-4[6], 
indicated a higher sensitivity and lower specificity of  0.88 
and 0.65, respectively, with a lower overall accuracy of  0.70. 
For stage F4 at a TE threshold of  > 12.5 kPa, sensitivity 
was lower at 0.72, but with a similar specificity of  0.89.
Baseline comparison of combined FibroSURE and TE
Both FS and TE results were available in 209 patients 
before therapy. For this subset, prediction of  stages F2-4 
using FS and TE in combination had a sensitivity of  
0.93, a specificity of  0.68, an AUROC of  0.88 (95% CI 
0.82-0.94), and an adjusted AUROC of  0.88 (Figure 1). 
Agreement between FS and TE, however, for F2-4 was 
0.71 (95% CI 0.65-0.77), with a Cohen’s κ of  0.41 (95% 
CI 0.30-0.52). Among 61 patients with nonconcordance 
for FS and TE, 88% (n = 54) were F2-4 by FS and F0-1 
by TE; biopsy indicated mild-stage disease in most of  
these 54 patients [F0-1 in 88.9% (n = 48); F2-4 in 11.1% 
(n = 6)]. Conversely, only seven of  the 61 patients were 
F0-1 by FS and F2-4 by TE; four of  these patients were 
F0-1 by biopsy.
For the 148 patients with agreement between FS and 
TE, 68% (n = 101) were stages F0-1 and 32% (n = 47) 
were F2-4 by both noninvasive tests. Biopsy results, 
however, indicated agreement with both FS and TE in 
86% (n = 128), with 3% and 11% misclassified by both 
noninvasive tests as F0-1 and F2-4, respectively. Biopsies 
were > 15 mm in 56 of  the patients for which there was 
agreement between FS and TE, and concordance results 
for the noninvasive tests were compared with the biopsy 
results: there was a slight reduction in the proportion of  
patients misclassified by the combination of  FS and TE 
(from 14.0% to 10.7%), although the sample size was 
relatively small. Agreement between FS and TE for stage 
F4 increased to 0.85 (95% CI 0.80-0.90; κ = 0.53), and 
compared with biopsy, misclassification rates (biopsy 
< F4) for both FS and TE were 7.3%, with all cases being 
false positives.
Changes in transient elastography during therapy
Results for TE were available in a subset of  217 patients 
who completed treatment (HCV Gt 1, n = 122; Gt 2/3, n 
= 95). Mean TE scores were lower at baseline in patients 
who achieved an SVR compared with NRs (8.0 vs 11.9 
kPa; P = 0.006). Further multivariate modeling showed no 
association with Gt, race, or body mass index, but signifi-
cant increases in liver stiffness in older patients (P < 0.001) 
and men (P = 0.03). In addition, TE scores were higher in 
patients with METAVIR grades 2-3 inflammatory activ-
ity score at baseline (11.8 vs 7.3; P < 0.001), with further 
minimal declines in TE measurements during therapy for 
patients with an SVR and NRs. The difference at baseline 
remained significant only at week 12 (P = 0.03) and lost 
significance at later on-treatment time points (Figure 3). 
At the follow-up visit, overall mean changes in TE from 
baseline were -1.3 kPa (P < 0.001) and -2.7 (P = 0.04) 
for patients with an SVR and NRs, respectively, reflect-
ing declines to levels that remained different (6.9 vs 10.1; 
P = 0.049). There was no correlation between changes in 
TE and alanine transaminase during or after therapy.
Changes in FibroSURE after antiviral therapy
Baseline FS scores were available in 2082 patients (HCV 
Gt 1, n = 1200; Gt 2/3, n = 882), with 1731 also avail-
able at post-treatment follow-up. Patients who achieved 
an SVR (n = 1305) had lower mean baseline FS fibrosis 
index scores compared with NRs (n = 777; 0.38 vs 0.51; 
Figure 1  Baseline area-under-the-receiver-operating-curve analysis for 
stages F2-4 for FibroSURE and transient elastography. Of the overall cohort 
with baseline biopsy (n = 2060), FibroSURE (FS) was available in 2055 patients, 
transient elastography (TE) in 214, and both FS and TE in 209. Area-under-the-
receiver-operating-curve values for stages F2-4 were 0.82 for FS, 0.88 for TE, 
and 0.88 for FS + TE. Differences between FS and TE were not significant. FS: 
FibroSURE; TE: Transient elastography.
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P < 0.001). Baseline FS necro-inflammatory activity 
scores were not significantly lower in patients with an 
SVR (0.45 vs 0.47; P = 0.06). At post-treatment follow-up 
week 12, there was a significant reduction in FS fibrosis 
scores from baseline in patients with an SVR compared 
with NRs (Δ = -0.06 vs 0.0; P < 0.001; Figure 4). As ex-
pected with a biochemical response that accompanies 
viral clearance, there was a significant reduction in FS 
necro-inflammatory activity scores in patients with an 
SVR compared with NRs following antiviral therapy (Δ = 
-0.35 vs -0.02, P < 0.001) (Figure 4).
FibroSURE and transient elastography in Asian patients
There were 253 Asian patients with a baseline biopsy 
(mean length 13.5 ± 8.4 mm), classified as stages F0-1 
in 75% (n = 190) and F2-F4 in 26% (n = 63). For F2-4 
with FS (n = 253), sensitivity was 0.90, specificity was 
0.60, and AUROC was 0.83. These results were compa-
rable to those in patients from a non-Asian region (NAR; 
n = 1802), with a sensitivity of  0.86, a specificity of  0.61, 
and an AUROC of  0.82 (Table 2). In comparison to FS, 
TE had a similar sensitivity (0.88), but a higher specific-
ity (0.92) and AUROC (0.92, P = 0.11); however, there 
were only 33 Asian patients with available TE. There was 
no difference in F2-4 prevalence between Asian patients 
with available TE (25%) and FS (24%). Despite the small 
cohort, TE results for F2-4 in Asian patients were com-
parable to those in NAR patients (n = 181, AUROC 0.92 
vs 0.87, P = 0.35). 
For patients with both noninvasive tests available (Asian, 
n = 33; NAR, n = 176), agreement between FS and TE for 
stages F2-4 was higher in Asian than in NAR patients [94% 
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Figure 3  Changes in transient elastography with therapy according to 
sustained virological response. Mean FibroScan fibrosis scores over time by 
sustained virological response status in patients with hepatitis C virus (A) geno-
types 2/3 and (B) genotype 1. FU: Follow-up.
Table 2  Performance of FibroSURE and transient elastography in patients from Asia vs  non-Asian regions
Test Region (n) F2-4 (%) Sens Spec PPV (%) NPV (%) Accuracy (%) AUROC
FS   Asia (253) 24.9 0.90 0.60 42.9 95.0 67.6 0.83
   NAR (1802) 17.4 0.86 0.61 31.9 95.4 65.5 0.82
TE Asia (33) 24.2 0.88 0.92 77.8 95.8 90.9 0.92
 NAR (181) 19.3 0.77 0.87 58.7 94.1 85.1 0.87
FS  + TE Asia (33) 24.2 0.88 1.00       100.0 96.2 97.0 0.97
 NAR (176) 19.3 0.91 0.68 40.8 97.0 72.7 0.88
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
Fi
br
oS
U
RE
 fi
br
os
is
 in
de
x 
sc
or
e
-0.04 -0.01
No SVRSVR
A
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
Fi
br
oS
U
RE
 in
fla
m
m
at
or
y 
ac
tiv
ity
-0.32
SVR
-0.01
No SVRB
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logical response. Changes in FibroSURE (A) fibrosis index and (B) inflamma-
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virological response status.
A�ROC: Area under the receiver operating curve; FS: FibroS�RE; NAR: Non-Asian region; NPV: Negative predictive value; 
PPV: Positive predictive value; Sens: Sensitivity; Spec: Specificity; TE: Transient elastography. 
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(κ = 0.86) vs 67% (κ = 0.35); P < 0.001]. The combina-
tion of  FS and TE improved the accuracy for F2-4 in both 
Asian (97.0%) and NAR patients (72.7%), with AUROC 
values of  0.97 and 0.88, respectively (Table 2).
Most patients from the Asian region with available FS 
or TE achieved an SVR (85%; n = 216) and thus com-
parisons with NRs were not feasible. Baseline FS fibrosis 
scores, however, were higher in Asian than in NAR pa-
tients with an SVR (0.45 vs 0.36; P < 0.001), likely reflect-
ing differences in F2-4 prevalence between the two study 
populations. Changes in FS fibrosis scores at week-12 
follow-up were also comparable between Asian and NAR 
patients with an SVR (Δ = -0.04 vs -0.06; P = 0.09). In 
addition, mean TE measurements were comparable at 
baseline between Asian and NAR patients with an SVR 
(8.8 vs 7.8 kPa; P = 0.56), with no significant differences 
in changes at week 12 (-0.14 kPa vs -0.25 kPa, P = 0.91) 
or after therapy (-1.4 kPa vs -1.3 kPa, P = 0.98).
DISCUSSION
This large prospective cohort study in patients with chro-
nic HCV provides validation of  the diagnostic utility of  
serum markers and TE in relation to biopsy and IFN-
based therapy. Few studies have addressed longitudinal 
changes in either serum markers or TE with therapy and, 
importantly, the present global study also provides the 
first evaluation of  both noninvasive tests in patients from 
the Asia-Pacific region with chronic HCV. One limitation 
of  this study was that TE data could only be obtained at 
40 non-US study sites, as this device is not yet approved 
for use in the United States. Despite the limited cohort 
size for TE (n = 214) compared with FS (n = 2055), in 
accordance with prior observations, the overall results of  
this study indicate that both FS and TE have potential 
utility in the detection of  moderate-severe-stage disease. 
However, the performance characteristics of  these non-
invasive tests (particularly TE) may be somewhat better 
for exclusion of  cirrhosis[6,23]. For stages F2-4, FS and TE 
were effective in both Asian and NAR patients, but the 
agreement and accuracy of  combined FS and TE were 
higher in the limited cohort of  Asian patients with both 
tests (n = 33). Changes in FS and TE in relation to SVR 
were similar for both Asian and NAR patients. 
This study shows that both pretreatment TE (n = 
217) and FS (n = 2082) scores were lower in patients who 
achieved an SVR than in NRs, and that these differences 
were maintained through week 12 of  therapy. Multivariate 
modeling indicated that older age and male sex (both pre-
dictive of  lower virological responses in chronic HCV) 
were also independently associated with higher TE mea-
surements at baseline. Other smaller studies, however, 
have failed to demonstrate similar baseline associations. 
A recent study from France evaluated TE and FS in 112 
patients with chronic HCV receiving antiviral therapy, 
but did not include baseline biopsy or evaluation during 
therapy[11]. That study did not find any significant differ-
ences at baseline between patients with an SVR and NRs. 
Another study assessed TE alone before and after ther-
apy in a Japanese chronic HCV cohort of  145 patients, 
and noted no differences at baseline between patients 
with an SVR and NRs[12]. Similar findings from another 
small French cohort evaluating TE alone have also been 
reported[24]. A recent meta-analysis of  longitudinal studies 
in viral hepatitis indicated that both FS and TE could es-
timate treatment effect on fibrosis progression, although 
TE appeared to have early variability on treatment due to 
possible changes in necro-inflammatory activity[25]. The 
present study suggests that FS and TE could provide 
useful adjunctive information for the prediction of  viro-
logical response prior to IFN-based therapy for chronic 
HCV. These noninvasive tests, however, likely reflect 
baseline differences in inflammatory response, but could 
complement established host-viral predictors of  virologi-
cal response to IFN-based therapy, such as HCV-RNA 
levels, viral Gt, race, and host IL28B polymorphism[26,27].
At follow-up, both FS and TE declined in patients 
who achieved an SVR. This is in accordance with prior 
observations that successful treatment with a biochemi-
cal response was associated with a decline in serum 
fibrosis marker indices or TE measurements in patients 
with chronic HCV[9-12,28,29]. A limitation of  this study is 
that post-treatment biopsies were not required as part of  
these two clinical registration trials, which would have al-
lowed for correlation between the observed declines in 
noninvasive test scores and changes in fibrosis or necro-
inflammation. TE measurements may vary significantly 
with immune-mediated inflammatory responses in pa-
tients with chronic hepatitis B virus[30]. In contrast to 
other studies in patients with chronic HCV[6], however, 
this study also demonstrated a significant association 
between TE and histological necro-inflammatory activity 
at baseline. This association may have implications for 
establishing TE thresholds for different fibrosis stages 
in chronic HCV and may also explain the decline in liver 
stiffness measurements in patients with an established 
SVR in the present cohort. In this study, 80% of  patients 
had no or mild fibrosis (stages F0-1) prior to treatment 
and thus were incapable of  achieving a significant regres-
sion in fibrosis.
Both Asian and NAR cohorts demonstrated com-
parable performance characteristics for FS and TE. The 
observed accuracy and specificity for prediction of  stages 
F2-4 in Asians, however, was higher in the small TE co-
hort. The combination of  FS and TE in Asian patients 
resulted in a high accuracy for prediction of  F2-4, with 
no false-positive results. Thus, biopsies for staging F2-4 
could have been avoided in almost all Asian patients in 
this small cohort of  33 patients. There was excellent 
agreement between FS and TE in Asian patients, and 
this may partly relate to a slightly higher prevalence of  
advanced-stage disease and lower body mass index in the 
Asian cohort. Furthermore, increased waist circumfer-
ence appears to be a common reason for failure of  TE in 
European cohorts[19]. Although there are potential issues 
in obtaining adequate TE measurements in Asian patients 
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due to a narrow intercostal space, this was not a limiting 
factor in the present study[13]. Thus, the combination of  
FS and TE in Asian patients with chronic HCV merits 
further evaluation.
One of  the strengths of  this study is that sample 
collections were standardized per protocol for the two 
phase Ⅲ clinical trials, laboratory assessments were per-
formed centrally, and all biopsies were evaluated by a 
single experienced liver histopathologist. Standardization 
significantly reduced the heterogeneity observed in prior 
studies comparing results across different geographic 
populations[23]. Biopsy sampling and observer error, 
however, are inherent limitations to the development and 
validation of  all fibrosis biomarkers[31]. The experience of  
the pathologist may be more important than biopsy char-
acteristics[32]. Furthermore, prior studies have indicated 
that the accuracy of  liver biopsy (and noninvasive tests) 
is dependent on sample size[9,33-35]. In contrast to these 
prior observations, no significant change in the diagnos-
tic accuracy of  FS for stages F2-4 in > 900 patients with 
biopsies > 15 mm was found in the present study. Of  
note, TE accuracy for F2-4 appeared to decline in > 80 
patients with this optimal biopsy length, although only 19 
with biopsy F2-4 were in this cohort.
Prior studies have suggested that noninvasive per-
formance indices for stages F2-4 and F4 are improved 
using sequential algorithms of  FS and TE[6], or aspartate 
aminotransferase-to-platelet ratio index and FS[36]. In the 
present study, the F2-4 results for combined FS and TE 
indicated a comparable AUROC and agreement (0.88 and 
71%, respectively) to those observed in a recent study 
from France in 302 patients with chronic HCV (0.91 and 
72%, respectively) with a higher prevalence of  advanced-
stage disease[37]. Although discordance rates between se-
quential FS and TE with biopsy were not reported in the 
French study, prior data from that cohort indicated 84% 
concordance between biopsy and FS/TE agreement. 
This observation is similar to the 86% agreement noted 
in the present study; however, in contrast to the French 
cohort, cases of  discordance between biopsy and FS/TE 
agreement were due to false positives with the noninva-
sive tests. In practical terms, agreement between FS and 
TE regarding prediction of  F2-4 in the present study co-
hort could have avoided 71% of  biopsies, although 10% 
of  patients would still have been misclassified as having 
significant fibrosis. The discordance rate between FS and 
TE was 29%, with biopsy and TE agreement in most of  
the cases that appeared to have mild-stage disease. As 
expected, misclassification rates and discordance between 
FS and TE with biopsy were significantly reduced for 
prediction of  F4.
With a broader range of  available therapeutic options 
for patients with chronic HCV in the future, noninvasive 
measures that can accurately exclude advanced-stage 
disease will likely assume a more significant clinical role 
in the treatment decision process. Recent mathematical 
modeling indicates that a perfect biomarker of  stages 
F2-4 may not exceed an AUROC of  0.9[38], and thus vari-
ous issues regarding biopsy sampling error and noninva-
sive test discordance should be individualized when using 
these tests to predict a threshold of  F2 in clinical prac-
tice. The observed heterogeneity among studies (including 
the present one) for optimized TE cutoffs indicates that 
a range of  liver stiffness measurements for each fibrosis 
threshold in patients with chronic HCV may be more ap-
propriate[39]. Standardization of  AUROC curves or other 
methods to reduce effects of  spectrum bias in disease 
prevalence allows for comparison of  FS across studies, 
including selected cohorts within studies, but not for TE 
due to variable optimal thresholds[21]. No significant dif-
ferences between observed and standardized AUROC 
values were found in the present study for either nonin-
vasive measure.
In summary, this study demonstrates that a combi-
nation of  serum and imaging noninvasive tests can be 
used for prediction of  at least moderate-stage disease in 
a global cohort of  patients with chronic HCV, including 
the potential of  higher accuracy for the combination of  
FS and TE in Asian patients. Furthermore, some baseline 
differences in index values for both FS and TE were de-
pendent on virological response and merit further evalua-
tion in the context of  IFN-based therapy.
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Background
Liver biopsy is an invasive procedure associated with significant costs and 
risk of complications. Noninvasive alternatives to biopsy for the determination 
of fibrosis stage include serum [FibroSURE (FS)] or imaging-based [transient 
elastography (TE) FibroScan] tests. The combination of these two modalities 
appears to have a good predictive value for excluding cirrhosis. Fibrosis is a 
predictor of virological response to chronic hepatitis C virus (HCV) therapy, and 
noninvasive tests may also be useful in this regard. Test values may vary with 
antiviral therapy for chronic HCV, perhaps due to changes in hepatic inflamma-
tion or with body habitus. Few studies have evaluated the utility of both these 
noninvasive modalities in patients with chronic HCV during interferon-based 
therapy, and there are limited data for these tests in Asian patients, particularly 
in comparison with non-Asian cohorts.
Research frontiers
Both FS and TE are validated measures for the noninvasive assessment of 
fibrosis. One important research issue is the determination of their utility in fol-
lowing changes in fibrosis or inflammation, e.g., as part of the natural history of 
disease or during and after antiviral therapy.
Innovations and breakthroughs
In this study, both FS and TE demonstrated good potential utility in the detec-
tion of moderate-severe-stage disease, but the performance characteristics of 
these noninvasive tests (particularly TE) may be somewhat better for exclusion 
of cirrhosis. Agreement between these tests and their accuracy for predicting 
disease stage may be higher in Asian than in non-Asian patients with chronic 
HCV. Patients that achieved a sustained virological response with interferon 
therapy appeared to have lower noninvasive test values at baseline. 
Applications
Both FS and TE appear to have good clinical utility in predicting moderate-se-
vere fibrosis prior to therapy, in both Asian and non-Asian patients with chronic 
HCV. Lower index scores at baseline may signify a better chance of responding 
to antiviral therapy. 
Terminology
FS comprises a combination of simple biochemical blood tests that predict 
fibrosis. TE is an ultrasound-based imaging method to measure liver stiffness, 
which also predicts fibrosis. 
Peer review
The authors investigated FS vs Fibroscan in treatment-naive patients with HCV. 
This article is unique and interesting.
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